First patent granted to Norwood Immunology
Tuesday, 17 February, 2004
Norwood Abbey (ASX:NAL) subsidiary Norwood Immunology has been granted its first patent, covering the use of GnRH analogues to increase the T cell population for the treatment of a variety of diseases.
The patent, granted in South Africa, is the first of more than 100 patent applications filed in major jurisdictions around the world covering various aspects of the immunology project.
Director of marketing Bernie Romanin said that the granted patent provided recognition of the breadth of the application of the GnRH technology.
Norwood Immunology is in the process of listing on the London Stock Exchange's AIM market. Romanin said the listing process was progressing according to plan and the company expected it to list mid-year.
Exclusive colostrum intake may reduce risk of food allergies
Newborns who are exclusively fed colostrum in the first 72 hours following birth are five times...
Sunscreen and supplements can lower your vitamin D levels
People who use SPF50+ sunscreen daily are more likely to be vitamin D deficient, while taking...
Low-dose drug prevents diabetes progression in young people
A low dose of the immunomodulatory drug anti-thymocyte globulin (ATG) appears safe and effective...
